Skip to content
OpenCapital
Get started

ADMA Biologics ADMA ASCENIV — Revenue

Other product segments

BIVIGAM
$15.42M-54.0%
Intermediates And Other
$833K-78.5%

Similar metrics at other companies

PTC Therapeutics logo
PTCTProduct — Revenue
$225.57M+47.0%
LQD
LQDAProduct — Revenue
$129.88M—
Nuvation Bio logo
NUVBProduct Revenue — Revenue
$18.5M+2,213%
Syndax Pharmaceuticals logo
SNDXProduct — Revenue
$48.92M+144%
Nuvation Bio logo
NUVBProduct — Revenue
$18.51M—
Iovance Biotherapeutics, Inc. logo
IOVAUS — Revenue
$70.47M+45.2%

Other financials

Income statement

See full
Revenue$114.5M-0.3%
Gross profit$80.8M+32.2%
Operating income$58.3M+67.1%
Net income$45.3M+68.5%
EPS (diluted)$0.19+72.7%

Balance sheet

See full
Cash & equivalents$138.2M+92.9%
Total debt$204.4M+2,055%
Total equity$390.3M+4.5%
Total assets$665.2M+30.3%

Cash flow

See full
Operating cash flow$58.2M+396%
CapEx$2.5M-45.9%
Free cash flow$55.7M+329%

Valuation

See full
Market cap$2.02B-54.5%

Profitability

See full
Gross margin61.3%+8.7pp
Operating margin42.1%+9.0pp
Net margin32.4%-12.6pp
FCF margin21.2%+1.4pp

Returns & leverage

See full
Return on equity43.3%-35.2pp
Debt / equity0.5×+0.5×
Current ratio7×+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's asceniv — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ADMA Biologics's ASCENIV — revenue?
ADMA Biologics (ADMA) reported ASCENIV — revenue of $97.49M in Q1 2026.
How has ADMA Biologics's ASCENIV — revenue changed year-over-year?
ADMA Biologics's ASCENIV — revenue increased by 27.7% year-over-year, from $76.33M to $97.49M.
What does ASCENIV — revenue mean?
This metric represents the total gross revenue generated from the sale of a specific biopharmaceutical product or therapeutic line after excluding any assessed taxes. It serves as a primary indicator of market adoption, commercial success, and the revenue-generating capacity of the specific product segment within the company's portfolio. Tracking this figure allows investors to evaluate the growth trajectory and competitive positioning of the product in the specialty biologics market.